Big Pharma teams up to tackle 'superbugs'; Indian drugmakers sign up to copy BMS hep C drug;

@FiercePharma: Vaccines present 'biggest breakthrough' in animal health: Report. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Poland says Mylan halted production at Agila Specialties plant after inspectors found issues. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals. FiercePharma article | Follow @CarlyHFierce

> Pharma giants including GlaxoSmithKline ($GSK) and Merck & Co. ($MRK) are teaming up to accelerate R&D on drugs and devices to treat antibiotic-resistant infections. Release

> The Medicines Patent Pool signed up four Indian drugmakers to manufacture copies of Bristol-Myers Squibb's ($BMY) hepatitis C drug daclatasvir under a license designed to give patients in low- and middle-income countries access to antiviral treatment. Report

> A New Jersey man sued Bristol-Myers Squibb and Otsuka Pharmaceuticals, claiming that their psychiatric drug Abilify caused him to develop a compulsive gambling habit. Report

Medical Device News

@FierceMedDev: IBM bets its future on machine learning and Watson Health. Article | Follow @FierceMedDev

@EmilyWFierce: Drug and diagnostic cos are teaming up to develop new antibiotics for superbugs. More from the WSJ (sub. req.) | Follow @EmilyWFierce

> GSK, Qualcomm rumored to form $1B med tech joint venture. Report

> Pelvalon launches vaginal insert for nonsurgical treatment of fecal incontinence. Story

> bioMérieux's bioTheranostics unit embarks on solo act with $32M in tow. Article

Biotech News

@FierceBiotech: ICYMI: Abingworth tees up a unique, $105M co-development fund for PhIII deals. Article | Follow @FierceBiotech

@JohnCFierce: J&J halts a depression program in the shadow of a fatal French trial. News | Follow @JohnCFierce

@DamianFierce: the FDA is handling its breakup with $SRPT very childishly. just be honest and direct and maybe you can stay friends. | Follow @DamianFierce

> GlaxoSmithKline scientists accused of stealing drug R&D secrets for China scheme. Report

> FDA snow day delays review of Sarepta's Duchenne drug. Item

> Alkermes slammed as top depression drug fails two PhIIIs. Article

CRO News

> Parexel moves to buy a pharma consulting firm. News

> Catalent extends its clinical supply biz into Japan. More

> BioClinica buys into cost management with its latest deal. Report

> Biosimilars developer Celltrion taps Medidata for trial tech. Story

> French CRO Biotrial tries to move forward after disastrous clinical study. Article

Pharma Manufacturing News

> China ingredient maker's plant found in 'devastated state' by authorities. News

> Catalent expanding Japanese manufacturing site to offer clinical services. Item

> FDA says microbial contamination found at Montana Compounding. Report

> FDA bans products from another Chinese plant. Story

> Pfizer reportedly striking deal with Polysan for Russian production. Article

Pharma Asia News

> Japan's Daiichi Sankyo, Coherus become players in Enbrel biosimilar race. More

> China FDA plowed through trial and new drug applications in 2015, commissioner says. Report

> Japan's Chiyoda plans on big growth in drug plant building. Story

> AstraZeneca survives Onglyza compulsory license challenge in India. Article

> Medical reps in India face the boot from doctors' offices. Report

And Finally... Yale University researchers say they've developed a questionnaire to predict which patients will respond to particular antidepressants. Report

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.